Court Finds in Favor of Mylan in Patent Infringement Suit Related to Certain Teva Copaxone® Patents

 Court Finds in Favor of Mylan in Patent Infringement Suit Related to Certain
                            Teva Copaxone® Patents

PR Newswire

PITTSBURGH, July 16, 2013

PITTSBURGH, July 16, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that Judge Katherine Forrest of the U.S. District Court for the
Southern District of New York has dismissed Teva's lawsuit alleging that
Mylan's Abbreviated New Drug Application ("ANDA") for its generic version of
Copaxone® (glatiramer acetate) would infringe four patents held by Teva (U.S.
Patent Nos. 66,514,938, 7,074,580, 7,163,802, and 7,615,359).

Mylan is appealing to the Federal Circuit a separate decision involving other
Teva patents (U.S. Patent Nos. 5,800,808, 5,981,589, 6,048,898, 6,054,430,
6,342,476, 6,362,161, 6, 620,847, 6,939,539 and 7,199,098), which were upheld
by retired Judge Barbara Jones of the Southern District of New York. Oral
argument on Mylan's appeal was held on May 7, 2013. Mylan anticipates that a
favorable appellate decision on these patents would clear Mylan for launch
upon receipt of final regulatory approval.

This press release includes statements that constitute "forward-looking
statements," including with regard to the settlement of the litigation. These
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Because such statements inherently
involve risks and uncertainties, actual future results may differ materially
from those expressed or implied by such forward-looking statements. Factors
that could cause or contribute to such differences include, but are not
limited to: any legal or regulatory challenges to the settlement; strategies
by competitors or other third parties to delay or prevent product sales; risks
inherent in legal and regulatory processes; and the other risks detailed in
the company's periodic filings with the Securities and Exchange Commission.
The company undertakes no obligation to update these statements for revisions
or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), 724.514.1968; Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.